BMS Just Ghosted a Decade-Old Partnership. Zymeworks Felt That.

BMS launched a restructuring program in early 2025 targeting $2 billion in annual cost savings by 2027. So far, the results have been blunt. Significant layoffs in New Jersey have been announced through WARN filings since early 2025, with additional cuts scheduled through 2026. Pipeline programs that don't scream "first-in-class" or "best-in-class" are getting the axe.

A Phase 1 bispecific inherited from a pre-acquisition deal? That's the definition of expendable.

Zymeworks Isn't Exactly Reeling

Losing potential milestones sounds devastating. But potential milestones are a bit like lottery tickets; they only pay out if everything goes perfectly. In practice, Zymeworks' business stretches well beyond this single BMS program.

The company pulled in $69.6 million in milestone payments in 2025 from a roster of partners that includes GSK, Johnson & Johnson, Daiichi Sankyo, and BeOne Medicines. Its Azymetric platform (the technology that makes these dual-targeting antibodies possible) is validated by a real, approved product: zanidatamab (Ziihera), a HER2-targeting bispecific that's on the market.

Zymeworks also has a deep bench of next-generation programs in the works. Two new bispecifics, ZW209 and ZW1528, have investigational new drug applications on track for 2026. A couple of antibody-drug conjugates (ZW191 and ZW251) are in Phase 1. And the company presented data on trispecific T cell engagers and a novel RAS-inhibitor ADC platform at AACR in April 2026.

In other words, Zymeworks has options. Losing the BMS deal stings, but it doesn't blow a hole in the hull.

The Bigger Picture: Bispecifics Are White Hot

The irony of BMS dropping a bispecific program is that BMS is simultaneously betting billions on bispecifics elsewhere. In June 2025, BMS struck an $11.1 billion deal with BioNTech for a PD-L1/VEGF-A bispecific antibody targeting solid tumors. That's the same modality, different molecule, wildly different price tag.

And BMS isn't alone. The bispecific antibody space has seen enormous deal activity. Takeda paid up to $11.4 billion for Innovent's PD-1/IL-2 bispecific. Genmab acquired Merus for $8 billion, largely for a late-stage bispecific with Breakthrough Therapy Designation. Eli Lilly signed a $2.6 billion platform deal with ABL Bio.

The pattern is clear: big pharma is hungry for bispecifics, but only the ones with strong clinical data or late-stage momentum. Early-stage, inherited programs from old deals? Those are getting left behind.

What Comes Next for Zymeworks

With the BMS collaboration officially over, Zymeworks gets full rights to the CD40/FAP program back. The company could partner it with a new pharma collaborator, develop it internally, or shelve it. Given the competitive landscape in bispecifics and the early stage of the program, finding a new suitor won't be automatic.

But Zymeworks' real value isn't in any single molecule. It's in the Azymetric platform itself, which converts standard antibodies into multispecific formats by tweaking amino acids in their structure. It's like having a universal adapter that plugs into multiple outlet types. That versatility, proven by zanidatamab's approval and a growing clinical pipeline, is what keeps big pharma coming back.

The BMS chapter is closed. For Zymeworks, the story is far from over.

One Failed Trial Just Gutted Indivior's Entire R&D Operation

Indivior's experimental opioid addiction drug flopped in Phase 2, and now the company is gutting its research team. Wall Street didn't flinch, but the long-term implications of becoming a one-drug company are harder to ignore.